Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Edwards Lifesciences Corp.

Related EW
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
Goldman's New Pair Trade Opportunity
Will Fund Managers Pump Up Edwards To New Breakout? (Investor's Business Daily)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Edwards Lifesciences Corp. (NYSE: EW), and raised its price target from $115.00 to $125.00.

Jefferies noted, “We published two physician surveys on transcatheter aortic valve replacement (TAVR), one of early adopters and the other of current non-users. Based on the results, which show strong and sustainable procedure growth, we are increasing our forecasts and target. We continue to rate EW shares Buy.”

Edwards Lifesciences Corp. closed on Thursday at $102.88.

Latest Ratings for EW

Aug 2015Credit SuisseAssumesOutperform
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (EW)

View Comments and Join the Discussion!

Get Benzinga's Newsletters